Investing.com -- Italian authorities appointed a special commissioner on Monday to help Novo Nordisk (NYSE: NVO) deliver its planned €2 billion ($2.34 billion) investment in a factory near Rome.

Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to the drugs remains challenging. The medications still amount to around $500 ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Terry Smith slammed two of Denmark’s largest life sciences companies — Novo Nordisk A/S and Coloplast A/S — after they ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of illegally selling cheaper copycats of Novo Nordisk’s weight-loss drug ...

Novo Nordisk launched its online pharmacy in March to offer a direct-to-patient channel for selling its weight loss drugs. Self-paying consumers can buy Wegovy for $499 per month through NovoCare ...